AI Summary & Key Takeaways
AI InsightKlimik Dergisi 2017; 30(Suppl. 1): 2-36
📌 3 Key Takeaways
Abstract
Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu tarafından, ilk olarak 2014 yılında tüm dünyada önemli bir sağlık sorunu olan hepatit C virusu (HCV) infeksiyonunun yönetimine ilişkin bir uzlaşı raporu hazırlanmış ve Klimik Dergisi'nde yayımlanmıştır. Kronik hepatit Recently, we needed to update this report considering the new developments in treatment of chronic hepatitis C (CHC). This new consensus report is based on review of current literature and international guidelines. Agreed recommendations are presented at the end of each section such as epidemiology and natural history of HCV infection, diagnosis of acute hepatitis C (AHC) and CHC, treatment of AHC, goals of CHC therapy and pre-therapeutic assessment of CHC therapy, indications for treatment, contraindications to therapy, direct-acting antivirals (DAA) in the treatment of CHC and drug-drug interactions in the treatment of DAA, resistance problem in DAA treatment and clinical assesment of resistance, monitoring and managing treatment safety and side effects, post-treatment follow-up of patients who achieve a sustained virological response (SVR), follow-up of patients who didn't achieve an SVR and prevention of HCV infection. Klimik Dergisi 2017; 30(Suppl. 1): 2-36
Özet
Previously a consensus report about management of hepatitis C virus (HCV) infection, a major health problem all over the world had been prepared by Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases. It was first published in the Klimik Journal in 2014 Recently, we needed to update this report considering the newdevelopments in treatment of chronic hepatitis C (CHC). Thisnew consensus report is based on review of current literatureand international guidelines. Agreed recommendations are presentedat the end of each section such as epidemiology andnatural history of HCV infection, diagnosis of acute hepatitis C(AHC) and CHC, treatment of AHC, goals of CHC therapy andpre-therapeutic assessment of CHC therapy, indications fortreatment, contraindications to therapy, direct-acting antivirals(DAA) in the treatment of CHC and drug-drug interactions inthe treatment of DAA, resistance problem in DAA treatmentand clinical assesment of resistance, monitoring and managingtreatment safety and side effects, post-treatment follow-up ofpatients who achieve a sustained virological response (SVR),follow-up of patients who didn’t achieve an SVR and preventionof HCV infection. Klimik Dergisi 2017; 30(Suppl. 1): 2-36.